GLENMARK PHARMACEUTICALS (NSE: GLENMARK) is a Pharmaceuticals & Biotechnology company listed on NSE and BSE.
It trades at ₹2,190.2, carries a market capitalisation of ₹61,807 Cr and is valued at a trailing P/E of 45.4×.
Over the trailing twelve months it reported revenue of ₹16,983 Cr and a net profit of ₹1,362 Cr.
It shows a five-year median return on equity of 10.5% and a debt-to-equity ratio of 0.00× as of FY26.
This page tracks every NSE and BSE corporate filing for GLENMARK PHARMACEUTICALS, each AI-summarised, alongside its financials, shareholding and post-announcement price reactions.
Is this a good business at a fair price?
Auto-derived verdict from fundamentals · as of FY26
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
